Sun Pharma has completed a 12 weeks trial of its psoriasis drug, MK 3222, but needs 52-124 weeks data to apply for a license with the US FDA, says Surajit Pal, pharma analyst at Prabhudas Lilladher.
Sun Pharma on Thursday said it has successfully completed three clinical trials for its psoriasis drug, MK 3222.
The company has completed a 12 weeks trial, but needs 52-124 weeks data to apply for a licence with the US FDA, says Surajit Pal, pharma analyst at Prabhudas Lilladher.
Pal does not expect move on revenue or income side till FY19-20 as far as the drug is concerned. Previous anti-psoriasis drugs will become generic in next two to three years, which will add to pricing pressure, he says.
However, he adds that Sun Pharma could expect sales of USD 200-300 million from MK 3222.
Pal maintains his price target on the company at Rs 873 and says that Aurobindo and Jubilant remains his top picks in the sector.
Watch video for more..
Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.
First Published on May 5, 2016 10:33 am